Lava Therapeutics gains as U.S. FDA allows lead drug clinical trial

LAVA Therapeutics NV

12/05/2022 16:30

** Shares of cancer drug developer  LVTX.O  rise 9.6% to $4,
on track for a second straight session of gains
    ** LVTX says the U.S. FDA cleared its application for a
clinical study of its lead drug candidate, LAVA-051, among
patients who have relapsed or are resistant to treatment for
three types of blood cancer  urn:newsml:reuters.com:*:nGNX4Nw6V4
    ** The company's early-to-mid stage trial among patients
with chronic lymphocytic leukemia, multiple myeloma and acute
myeloid leukemia has already received clearance in Europe and
the company began dosing in July 
    ** The clearance from the U.S. FDA enables LVTX to expand
patient enrollment into the U.S for the trial- company
    ** Stock down 27% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))